What AGC Biologics’ role in Waskyra tells us about the future of ethical cell therapy scale-up
Waskyra’s FDA and EMA approvals spotlight AGC Biologics’ rare disease manufacturing model. Find out what this means for future nonprofit-led therapies.
Pharma & Biotech
Pharma & Biotech
Waskyra approved for Wiskott-Aldrich syndrome: What it means for stem cell alternatives
Fondazione Telethon has received regulatory approval from the United States Food and Drug Administration for Waskyra (etuvetidigene autotemcel), an ex vivo gene therapy designed to treat Wiskott-Aldrich syndrome, a rare X-linked primary immunodeficiency. This approval makes Waskyra the first gene therapy for this condition cleared for use in the United States and solidifies Fondazione Telethon’s